Amgen to Present Landmark Repatha Trial Results at AHA 2025

Amgen has declared that new findings from its cardiovascular portfolio, which includes late-breaking results from the phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab), will be showcased at the American Heart Association (AHA) Scientific Sessions scheduled for November 7-10, 2025, in New Orleans, LA.

 During the late-breaking scientific session titled "Groundbreaking Trials in Cardiometabolic Therapeutics" on Saturday, November 8 at 9:10 a.m. CST (Abstract #LBS.01), results from the pivotal phase 3 VESALIUS-CV clinical trial of Repatha in patients at high cardiovascular risk who have not experienced a prior heart attack or stroke will be presented.

Also Read: Fujifilm India Unveils AI-Powered CAD EYE Endoscopy in Jaipur

It was revealed in October 2025 that the trial successfully met its dual primary endpoints, confirming that Repatha is the first and only PCSK9 inhibitor to significantly lower the risk of major adverse cardiovascular events (MACE) in individuals without a previous history of heart attack or stroke.

"With powerful new data that reinforce the importance of early intervention and sustaining low LDL-C levels, Repatha is the first and only PCSK9 inhibitor to demonstrate an improvement over optimal lipid-lowering therapy to prevent a first heart attack or stroke," said Jay Bradner, M.D., executive vice president of research and development at Amgen. "All the data we will present at the American Heart Association Scientific Sessions underscore the breadth of our ongoing cardiovascular research across diverse populations and risk profiles.

The size, scope and ambition of our program, including clinical trial and real-world data, demonstrate Amgen's unwavering commitment to people living with cardiovascular disease."